With a few recent exceptions, the outcomes of randomized clinical trials in acute heart failure (AHF) have been disappointing. [1] [2] [3] [4] [5] Methodological aspects of clinical trials in terms of study design, end point and patient selection, and intrinsic properties of the experimental interventions could account for some of these unsatisfactory findings. 6 Because AHF is heterogeneous in its etiology, pathophysiology, and clinical presentation, it should perhaps not be treated as a single clinical entity. It is plausible that although some treatments may have better efficacy in certain patient populations, they may not be as effective in others and therefore, on average, fail. Hence, a better segmentation of the AHF patient population and development of therapies that target specific pathophysiological mechanisms might yield greater success than would a "one-size-fits all" model.
The clinical presentation of AHF can be diverse. 7 Although dyspnea is typically the most common cause for patients seeking consultation, many patients with AHF also present with varying degrees of peripheral edema. 8, 9 The underlying pathophysiology and therapeutic needs for patients presenting with progressive increase in exertional dyspnea and severe peripheral edema may be different from those who present with a sudden onset of severe dyspnea at rest with little or no peripheral edema. Patients in the latter group develop symptoms and signs of pulmonary congestion without overt evidence of fluid retention. This suggests fluid redistribution into the lungs as the underlying pathophysiological mechanism requiring immediate medical intervention with vasodilator rather than diuretic agents. [9] [10] [11] A minority of patients with AHF are also admitted with clear signs and symptoms of hypoperfusion and low cardiac output (cardiogenic shock), representing a subgroup of patients with AHF with an ominous prognosis. 7, 8 Serelaxin is a recombinant protein identical in structure to the naturally occurring human pregnancy hormone, relaxin-2.
1,2 Previous trials have shown that serelaxin improves dyspnea and signs of congestion, and, subsequently, reduces cardiovascular (CV) and all-cause mortality for up to 6 months after completion of 48-hour intravenous (IV) infusion. 1, 2 Whether there are differences in baseline characteristics and outcomes in patients with peripheral edema vs those without is unknown. We therefore investigated the characteristics, therapeutic response, and outcome of patients enrolled in the RELAX-AHF trial who at baseline had either substantial peripheral edema, indicating progressive fluid accumulation, or mild/no peripheral edema, suggesting fluid redistribution as the dominant underlying pathophysiology. 9 
Methods
This is a post hoc analysis of the RELAX-AHF trial (ClinicalTrial.gov identifier: NCT00520806). RELAX-AHF was an international, multicenter study that compared the efficacy of serelaxin vs placebo, in addition to standard of care, in patients admitted with AHF. The trial design and results have been reported previously. 1, 12 Patients were randomized within 16 hours of hospital presentation to either receive IV serelaxin or matching placebo for 48 hours, in addition to the standard of care for AHF. Prespecified eligibility criteria included breathlessness at rest or from minimal exertion, elevated plasma concentrations of natriuretic peptides (brain natriuretic peptide [BNP] ≥350 pg/mL or N-terminal fragment of pro-BNP [NT-pro-BNP] ≥1400 pg/mL), a chest X-ray with an evidence of pulmonary congestion, mild to moderate renal insufficiency (estimated glomerular filtration rate [eGFR] ≥30 to ≤75 mL/min per 1.73 m 2 ), systolic blood pressure N125 mm Hg, and should have received at least 40 mg of IV furosemide (or equivalent) therapy before screening. 1, 13 The key outcome measures for this analysis are described in the Statistical analysis section. The in-hospital phase focused on symptoms and signs at different time points, diuretic requirements, blood pressure (BP) and length of stay (LOS). Worsening heart failure (WHF) was assessed through day 5 and morbidity and mortality were assessed up to 6 months.
Data collection
During the RELAX-AHF trial, investigators assessed the signs and symptoms of AHF including dyspnea on exertion (New York Heart Association [NYHA] class), orthopnea, rales, jugular venous pressure (JVP), and the presence of peripheral edema at scheduled time points through day 14. These physician assessments of signs and symptoms were scored as follows: dyspnea on exertion (none, mild, or moderate) or at rest (severe) corresponding to NYHA classes I-IV, clinical evidence of pulmonary congestion assessed by auscultation (no rales, rales b1/3, 1/3-2/3, or N2/3), orthopnea (none, 1 pillow, 2 pillows, or N30°), and JVP (b6 cm, 6-10 cm, N10 cm, or not evaluable). Peripheral edema was assessed on a 0-4 scale, with scores of 0 to 1+ classified as no or mild edema and 2+ and 3+ as moderate to severe edema. Only baseline edema was used to define the subgroups. Body mass index (BMI) was based on actual weight uncorrected for the severity of edema.
Statistical analysis
Baseline characteristics (including demographic, clinical, and HF characteristics) were summarized using descriptive statistics (ie, n, mean, SD, 95% CI, median, interquartile range [IQR], minimum, and maximum).
For continuous variables, subgroups were compared using 2-sample t tests or Wilcoxon rank sum test as appropriate, and categorical variables were compared using χ 2 tests. For each efficacy end point, within each of the subgroups, treatment effects were assessed using an analysis of covariance (ANCOVA) model for continuous outcomes and the least square mean (LSM) difference was reported accordingly. Logistic regression was used to assess the treatment effects for binary outcomes and the odds ratios (ORs) was provided. For time-to-event outcomes, treatment effects were assessed by Cox proportional hazard regression analysis and the hazard ratios (HRs) were reported.
The 95% CIs for each of the above-estimated treatment effect along with the P value for between-treatment comparisons were reported based on the aforementioned statistical models including treatment (serelaxin vs placebo) as a major factor. In addition, for each of the time-to-event outcomes, P values for treatment effects based on the log-rank test were also reported within each subgroup. Possible subgroup-by-treatment interactions were assessed from a separate model including the 2 subgroups, treatment arms, and the subgroup-by-treatment interaction in the model. The P value based on the type 3 χ 2 test for the subgroup-by-treatment interaction term was reported accordingly. Because the end points, "length of initial hospital stay," "days in intensive care unit/cardiac care unit (ICU/CCU)" and "days alive out of hospital through day 60" do not follow the normality assumption for parametric tests, the treatment effect was expressed as median difference and 95% CI based on Hodges-Lehmann estimation in addition to the LSM and 95% CI. The P values were based on nonparametric Wilcoxon rank sum test.
Kaplan-Meier plots for the estimated cumulative event rate over time were provided for the 2 treatment arms within each of the 2 subgroups (a total of 4 curves) for the following time-to-event outcomes: all-cause and CV mortality through day 180, and WHF through day 5.
For all analyses, 2-sided P values with an α level of .05 were considered as statistically significant. All analyses were conducted on an intent-to-treat basis. Statistical Analysis software (SAS) release 9.4 (SAS Institute, Cary, NC) was used for all analyses.
The RELAX-AHF study and this analysis were sponsored by Novartis Pharma AG. The authors are solely responsible for the design and conduct of this study, all study analyses, and drafting and final contents of this manuscript. The editorial and formatting support for the manuscript was provided by a scientific writer.
Results
Of the 1,161 patients randomized in the RELAX-AHF trial, 1,154 reported the presence or absence of peripheral edema at baseline. Of these, 583 (50.5%) had little or no edema (no/mild edema subgroup) and 571 (49.5%) had overt peripheral edema (moderate/severe edema subgroup).
Patients in the no/mild edema subgroup were slightly older, had a lower BMI, and were more often women, compared with those in the moderate/severe edemas subgroup (Table I) . Clinical signs, including BP, heart and respiratory rates, and patient-reported severity of dyspnea at baseline (assessed by the visual analog scale [VAS] score) were similar in both the subgroups. Time from presentation to randomization was shorter for the moderate/severe edema subgroup (7.3 hours) compared with the no/mild edema subgroup (8.5 hours; P b .0001) ( Table I) .
Physician assessment of signs and symptoms of HF at baseline indicated that a higher proportion of patients in the moderate/severe edema subgroup, compared with the no/mild edema subgroup, had severe dyspnea (71.1% vs 60.5%, respectively; P = .0002), severe orthopnea (N30°, 45.1% vs 34.0%; P b .0001), and overt signs of pulmonary congestion as demonstrated by the presence of rales ≥1/3 (60.6% vs 48.2%; P b .001). The proportion of patients with an elevated JVP (≥6 cm) was also higher in the moderate/severe edema subgroup than the no/ mild edema subgroup (P b .0001) ( Table I ).
There were no baseline differences between the 2 subgroups with regard to history of hypertension and ischemic heart disease, NYHA class before admission, or left ventricular ejection fraction (LVEF) ( Table I) . However, patients in the moderate/severe edema subgroup were more likely to have a history of congestive HF, were more likely to have been hospitalized for HF in the past year, had a higher prevalence of atrial arrhythmias and diabetes mellitus, and were more likely to have an implantable cardiac defibrillator with or without biventricular pacing (P b .05 for all). Each subgroup received similar background treatment for HF at baseline (Table II) . Patients in the moderate/severe edema subgroup had higher plasma concentrations of creatinine (P = .032), uric acid (P = .0018), blood urea nitrogen (P = .0002) and cystatin C (P b .0001) than did patients in the no/mild edema subgroup, whereas the eGFR was similar in both subgroups (P = .27). Plasma BNP and NT-proBNP levels and the proportion of patients with an elevated troponin T levels at baseline were also similar between subgroups (Table II) . Analysis of NT-proBNP levels in patients with or without atrial fibrillation (AF) at baseline indicated that in patients without AF, plasma NT-proBNP was higher in the no/mild edema subgroup compared with the moderate/severe edema subgroup (median [IQR] 5110 [2732.0, 9904.5] ng/L vs 4124 [2379.0, 8147.0] ng/L; P = .0257). In contrast, no significant differences in NT-proBNP levels were observed between the 2 subgroups in patients with AF (Table II) .
Compared with placebo, serelaxin improved patient-reported dyspnea (VAS scores) in both subgroups, with a trend toward greater benefit in those with moderate/severe edema (Table III) . No difference was observed in the assessment of dyspnea by the Likert scale at 6, 12, and 24 hours in both subgroups (ORs 0.99 and 1.10 in the moderate/severe and no/mild edema subgroups, respectively, P for interaction = .6983).
Patients assigned to serelaxin received lower cumulative doses of diuretics in both the subgroups, with the difference being statistically significant in the moderate/ severe edema subgroup (serelaxin vs placebo mean difference: no/mild edema subgroup, −22 mg [P = .1845] and moderate/severe edema subgroup, − 78 mg [P = .0179]), although the test for interaction was not significant (P value for subgroup-by-treatment interaction = .1249). For patients with moderate/severe edema, reductions in body weight were similar for those assigned to serelaxin or placebo (LSM difference [95% CI] −0.005 [−0.6 to 0.6] kg), whereas in those with no/mild edema, a larger decrease in body weight was noted in patients assigned to placebo (LSM difference [95% CI] 0.48 [0.07-0.9] kg, P = .0225).
In the no/mild edema subgroup, serelaxin-treated patients had a significantly shorter index LOS and time spent in ICU/CCU compared with the placebo group (mean LOS, serelaxin: 8.3 days vs placebo: 10.1 days, P = .0035; ICU/CCU stay, serelaxin: 2.7 days vs placebo: 3.8 days, P = .0282). However, no significant differences .0109 ⁎ Intention-to-treat set with nonmissing baseline edema score; data are presented as mean (SD) unless otherwise specified. Abbreviations: AF, atrial fibrillation; BP, blood pressure; COPD, Chronic obstructive pulmonary disease; DOE, dyspnea on exertion; HF, heart failure; JVP, jugular venous pressure; VAS, visual analogue scale. ⁎ Significant difference between "no/mild edema" vs "moderate/severe edema," P b .05. † P values were based on 2-sample t test for continuous variables and χ 2 test for categorical variables. ‡ Severity of dyspnea on exertion was assessed as none (score = 0), mild (score = 1), moderate (score = 2), and severe including dyspnea at rest (score = 3). § Severity of orthopnea assessed as none (score = 0), 1 pillow, 10 cm (score = 1), 2 pillows, 20 cm (score = 2), and N30°(score = 3). ║ Rales assessed as no rales (score = 0), rales b1/3 (score = 1), rales 1/3-2/3 (score = 2), and rales N2/3 (score = 3). ¶ JVP assessed as b6 cm (score = 0), 6-10 cm (score = 1), and N10 cm (score = 2). # There were 2 subjects in the "no/mild edema" and 8 subjects in the "moderate/severe edema" subgroup with history of congestive heart failure but without NYHA classification.
between the serelaxin and placebo arms were observed in the moderate/severe edema subgroup; furthermore, no significant interaction between subgroup and treatment was observed (P = .0667 for LOS and P = .0835 for ICU/CCU stay).
No significant differences were observed in the days alive and out-of-hospital end point or in the composite end point of CV death or HF/renal failure rehospitalization through day 60 across subgroups and treatment arms. Overall, serelaxin reduced all-cause mortality through day 180 compared with placebo. 
Discussion
In this post hoc analysis, patients with AHF from the RELAX-AHF trial were classified into 2 subgroups based on the absence or presence of baseline peripheral edema: ║ Continuous variables are expressed as mean (SD) or geometric mean (95% CI) and categorical variables as n (%), Abbreviations: ACE, Angiotensin-converting enzyme; BUN, blood urea nitrogen; ICD, implantable cardiac defibrillator; MDRD, Modification of Diet for Renal Disease. ⁎ Significant difference between "no/mild edema" vs "moderate/severe edema," P b .05. † P values were based on 2-sample t test for continuous variables and χ 2 test for categorical variables. ‡ eGFR calculated by the simplified MDRD formula § For the biomarkers, the summary statistics of median and IQR and P values based on nonparametric Wilcoxon test are provided. ║ P value was based on analysis of variance including natural log-transformed NT-proBNP at baseline as the dependent variable and subgroup as the major factor. Table III . Treatment effect (serelaxin vs placebo) on various outcomes in patients with "no/mild edema" (baseline edema score = 0/1) and "moderate/severe edema" (baseline edema score = 2/3)
Outcome
No/mild edema (total n = 583) Moderate/severe edema (total n = 571) Continuous variables are expressed as mean (SD), categorical variables as n/N (%), and time-to-event variables as n/N (%) + (KM %); n′ = number of subjects with nonmissing data. Abbreviations: AUC, Area under the curve; HF, heart failure; IQR, interquartile range; LR, logistic regression; KM, Kaplan-Meier; RF, renal failure. ⁎ Significant difference between "no/mild edema" vs "moderate/severe edema," P b .05. † Treatment effect represents LSM difference for continuous variables, OR for dichotomous variables, and HR for time-to-event variables, estimated from ANCOVA model, logistic regression, and Cox regression models, respectively. The 95% CIs for the above-estimated treatment effect along with P value for between treatment comparison and subgroup-by-treatment interaction are reported based on the aforementioned statistical models respectively. ‡ Dyspnea improvement to day 5 as assessed by VAS-AUC. § Subjects with moderately or markedly better dyspnea as assessed by the Likert scale. ║ For the end points, "length of initial hospital stay," "days in IC/CCU," and "days alive out of hospital through day 60"; the summary statistics of median and IQR are also presented and the treatment effect is expressed as median difference and 95% CI based on Hodges-Lehmann estimation. P value is based on nonparametric Wilcoxon rank sum test. ¶ LR: P value of treatment effect for time-to-event end points is based on log-rank test. # Kaplan-Meier cumulative event rates. Kaplan-Meier curves for all-cause mortality through day 180 (A), CV mortality through day 180 (B), and WHF through day 5 (C). PBO, placebo; RLX030, serelaxin. ⁎ Significant difference between "no/mild edema" vs "moderate/severe edema," P b .05. a no/mild and moderate/severe. The subgroup definition was an attempt to discern 2 different phenotypes of patients with AHF, with possible differences in the underlying pathophysiology (fluid retention vs fluid redistribution) based on a very simple clinical variable. The analysis suggests that patients admitted with severe peripheral edema generally have worse outcomes but benefit from the administration of serelaxin as much in relative terms and perhaps, more in absolute terms, as do those admitted for breathlessness without an evidence of marked fluid retention. This suggests that serelaxin may not be acting solely as a vasodilator agent to reduce pulmonary capillary pressure and fluid redistribution. Improved renal function and reduction in diuretic requirements in patients treated with serelaxin point to a possible renal effect.
Importantly, the 2 subgroups in this analysis were of similar size. Some of the differences in baseline characteristics were not unexpected: a higher proportion of female representation, slightly older population, and lower BMI were observed in the no/mild subgroup. In the moderate/severe subgroup, the proportion of patients with a history of hospital admission due to HF within the last year was higher and statistically significant. This was consistent with their baseline characteristics of a history of HF and, consequently, an increased proportion of associated comorbidities such as diabetes, AF, and higher levels of renal markers suggesting more severe chronic kidney dysfunction.
We observed higher NT-proBNP levels in patients without AF at screening in the no/mild edema group compared with moderate/severe edema group. These findings are somewhat counter intuitive, as increased NT-proBNP levels would be expected both in patients with moderate/severe edema (as a consequence of the fluid overload) and the subgroups with AF at screening as compared with those without, because AF is a known independent determinant of increased NT-proBNP. Although this observation could be a chance finding, it could also be due to differences in certain baseline characteristics such as renal function, paroxysmal AF after screening, age, gender differences, and so on.
Although we expected a higher LVEF in the no/mild group, the mean LVEF (approximately 38%) was similar in both subgroups. A medical record review of echocardiograms as opposed to index visit echocardiograms may have contributed to this finding. The distribution of patients with AHF into those with mild or no peripheral edema vs those with moderate to severe peripheral edema are consistent with previous registry data collected from more than 136,000 patients during 6 years in England and Wales. 14 A similar useful and simplistic classification of patients with AHF into "puffers" and "bloaters" was described by Clark and Cleland 15 and Gheorghiade et al. 16 A classic "bloater" presents with increasing water retention, weight gain, peripheral edema, and renal dysfunction.
These patients have more severe pulmonary hypertension, right ventricular dysfunction, and tricuspid regurgitation. 17 Hepatic congestion impairs degradation of aldosterone which exacerbates sodium and fluid retention. These patients usually have a subacute presentation, and emergency treatment is often not required; yet they have a particularly poor prognosis. Some patients under the "bloaters" group may not seek medical attention until pulmonary edema and severe breathlessness develop. 15 In contrast, many "puffers" have little evidence of fluid retention. Their underlying problem appears to be redistribution of fluid from the circulation to the pulmonary alveoli due to capillary hypertension, which is often associated with an increase in systemic vascular resistance and an increased afterload. This may be driven by a vicious cycle of increased sympathetic activation driven in part by the distress caused by dyspnea. Patients in this group may be better treated by vasodilators rather than diuretic agents. 15 They typically present with a short history of severe breathlessness, requiring urgent treatment for symptom control. Many patients, however, fall between the extremes of these 2 presentations.
Although it can be argued that the presence of edema may be associated with multiple different clinical and pathophysiological conditions (eg, nutrition and protein levels, endothelium integrity, venous competence, renal function etc.) and that the specificity of the evaluation is not very high, this "bedside assessment" is a simple clinical tool providing a first impression of the patient's phenotype. However, this must be confirmed by further assessments with complementary analyses. 15, 18, 19 Although this classification is useful to understand the complexity of AHF presentation, it is not universally adopted. In the recently published European Society of Cardiology guidelines, an algorithm to characterize the hemodynamic profile of patients with AHF clearly shows that the presence of congestion (ie, "wet") is the most common presenting feature representing nearly 95% of patients with AHF. The same algorithm also describes that most patients are "wet" (congested) and "warm" (well perfused), typically presenting with normal or elevated BP. The algorithm further subcategorizes this population into vascular type-fluid redistribution (ie, hypertension predominant) or cardiac type-fluid accumulation (ie, congestion predominant). 18 In the present analysis, a statistically significant positive effect of serelaxin on dyspnea was observed in the moderate/severe edema subgroup, whereas a positive trend was also seen in the no/mild edema subgroup.
In accordance with our previous observations, no significant differences in the treatment effect were observed in the short-to medium-term outcomes, as assessed by CV death through day 60 or the composite end point of CV death or HF/renal failure hospitalization at 60 days.
1 A significant reduction in LOS was observed in the serelaxin-treated patients with no/mild edema.
Overall, the mean dose of IV diuretic up to day 5 was lower in serelaxin-treated patients in both subgroups. Although no significant treatment differences in diuretic use were observed in the no/mild subgroup (serelaxin vs placebo), this was particularly evident and statistically significant in the moderate/severe edema group. The serelaxin-treated patients in this subgroup required almost 80 mg less furosemide than did the placebo-treated patients, despite both treatment arms showing similar decreases in body weight. This finding is in contrast with previous analyses on the diuretic response, which did not identify any potentiation effect of serelaxin. 20 However, the same study suggested that a better diuretic response is expected in patients with more peripheral edema, an assumption that is supported in the present analysis. 20 The reduction in WHF through day 5 is consistent with that seen in the main population.
1 This is important for 2 reasons: (a) WHF has been recognized as a valid end point and has been demonstrated to have a good correlation with mortality, 21 and (b) increased validity of the WHF end point for regulatory agencies. In the future, should these results be validated in prospective trials, this end point could be used as a surrogate for mortality.
In accordance with the earlier observations, all-cause and CV mortality were lower in patients assigned to serelaxin 1 with similar relative benefits in each subgroup. Indeed, the absolute benefit with serelaxin on all-cause mortality and WHF appeared somewhat greater in those with more severe edema.
Contrary to what might be intuitively expected from a characteristic arterial vasodilator (ie, a better response in those with fluid redistribution rather than fluid retention), this analysis suggests that benefits may be similar or greater in those with overt evidence of fluid retention.
Studies in preclinical models suggest a selective vasodilatory effect of serelaxin on certain venous vascular beds (such as renal and mesenteric beds). 22, 23 Furthermore, preclinical and clinical evidence suggests that serelaxin reduces markers of renal and hepatic impairment possibly owing to its early decongestion effects and vasodilatory actions that improve perfusion and renal hemodynamics. 24, 25 In accordance with these observations, we speculate that a putative target effect of serelaxin on these vascular beds could contribute to increased venous capacitance and decongestion of the kidney, liver, and splanchnic tissue with potential long-term benefits. Alternatively, or in addition, specific effects on renal hemodynamics may improve diuretic responsiveness and unload the heart. This supports a targeted and specific mechanism of action that needs to be elucidated further.
Limitations
This was a post hoc analysis and because the number of patients in each subgroup was small, the results should be interpreted with caution. Similarly, differences in the baseline characteristics of the population (eg, different rates of AF across groups and indicators of heart failure duration) could have contributed to the current observations. Some patients may have been misclassified either because of interobserver variability or because of the arbitrary definition applied to what is possibly a continuous distribution. A larger study might allow more complex classifications to be applied with more granular subgroups.
Conclusions
Patients with AHF and more severe peripheral edema have a worse prognosis but appear to receive similar relative (and perhaps greater) absolute benefit from administration of serelaxin for several outcomes, including early WHF, CV, and all-cause mortality. Future trials in AHF (particularly RELAX-AHF-2) will help to determine the validity of these observations.
